Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

NCT01677559 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma
Pancreatic Neoplasms

Interventions

DRUG: MLN8237
DRUG: nab-Paclitaxel

Sponsor

Washington University School of Medicine